FRM
NRIX icon

Fox Run Management’s Nurix Therapeutics NRIX Stock Holding History

Fox Run Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,489
Closed -$213K – 1187
2026
Q1 		$213K Buy
+14,489
New +$240K 0.04% 748
2025
Q3 		– Sell
-18,902
Closed -$215K – 1137
2025
Q2 		$215K Buy
+18,902
New +$204K 0.04% 736

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fox Run Management's NRIX Position: Q2 2026 in Review

Fox Run Management sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 14,489 shares — an estimated $213K sold.

Fox Run Management first reported a position in NRIX in Q2 2025 and held it in 2 quarters. The position peaked at $215K in Q2 2025. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Fox Run Management reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 14,489 Nurix Therapeutics shares in Q2 2026, an estimated $213K.
  • Fox Run Management first reported a position in Nurix Therapeutics in Q2 2025 and held it in 2 quarters.
  • Fox Run Management's Nurix Therapeutics position peaked at $215K in Q2 2025.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.